ImmuCell

Historical price data

ImmuCell Corporation (NASDAQ: ICCC) is a vertically integrated animal health biotech focused on developing and manufacturing products to combat costly production diseases in cattle. Its mission is to deliver scientifically advanced, economically valuable solutions to dairy and beef producers, exemplified by its commercial product First Defense® and its pivotal-stage candidate, Re-Tain™. The company's strategy centers on maintaining full control over its value chain from its Portland, Maine facility, targeting niche indications with high unmet need to secure sustainable growth within the robust animal health market.

ImmuCell's core platform leverages hyperimmune antibody technology for passive immunization and a targeted antimicrobial peptide (nisin) platform for treating bacterial infections, both specifically designed for livestock health.

ImmuCell competes with animal health giants like Zoetis and Merck in niche segments. Its key competitive advantages are vertical integration, deep product expertise, and Re-Tain™’s unique zero milk discard profile. The primary challenge is the vast sales and marketing resources of its larger rivals.